Lopinavir NEW
| Price | $41 | $66 | $198 |
| Package | 50mg | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: Lopinavir | CAS No.: 192725-17-0 |
| Purity: 99.62% | Supply Ability: 10g |
| Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | Lopinavir |
| Description | Lopinavir (ABT-378) is a peptidomimetic HIV protease inhibitor effective against HIV protease with the Val 82 mutation. It is less affected by serum protein binding compared to the structurally related drug ritonavir. |
| In vitro | Administering Lopinavir (10 mg/kg, p.o.) to rats resulted in a maximum concentration (Cmax) of 0.8 μg/mL, with the drug's bioavailability being 25%. |
| In vivo | Lopinavir is an effective inhibitor of Rh123, with an IC50 value of 1.7 mM for Caco-2 cell monolayers. It binds to mutant HIV proteases (V82A, V82T, and V82F) with Ki values of 4.9, 3.7, and 3.6 pM, respectively. At a concentration of 0.5 nM, Lopinavir inhibits the activity of wild-type HIV protease by 93%. It also inhibits HIV protease activity in MT4 cells both in the presence and absence of 50% HS, with EC50 values of 102 nM and 17 nM, respectively. In liver microsomes, Lopinavir is converted to primary metabolites M-3 and M-4, a process that is NADPH-dependent. After treating LS 180V cells with Lopinavir for 72 hours, there is a reduction in intracellular Rh123 content and induction of P-glycoprotein immunoreactive protein and mRNA levels. Lopinavir exhibits an IC50 of 9.4 nM against subtype C clone C6. When acting on human liver microsomes, Lopinavir shows an IC50 of 7.3 mM against CYP3A and exerts weak inhibition on human CYP1A2, 2B6, 2C9, 2C19, and 2D6. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 116 mg/mL (184.48 mM), Sonication is recommended. DMSO : 247.5 mg/mL (393.61 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (6.36 mM), Sonication is recommended. |
| Keywords | wild-type | SARS-CoV | SARSCoV | SARS coronavirus | replication | mutant | Lopinavir | Inhibitor | inhibit | infection | Human immunodeficiency virus | HIVProtease | HIV Protease | HIV | coadministration | ABT378 | ABT 378 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Dolutegravir intermediate-1 | Dimethyl fumarate | Hydroxychloroquine | Lamivudine | Valproic Acid | α-Cyclodextrin | (-)-Epigallocatechin Gallate | Decanedioic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Orally Active Compound Library | Bitter Compound library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-29 | ||
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-26 | ||
|
VIP6Y
|
Sinoway Industrial co., ltd.
|
2026-06-22 | ||
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-06-12 | ||
| $1556.00 |
VIP6Y
|
Baoji Guokang Healthchem Co., Ltd.
|
2026-05-15 | |
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
| $150.00 |
Hebei Zhuanglai Chemical Trading Co Ltd
|
2025-05-23 | ||
| $26.00 |
Wuhan Boyuan Import & Export Co., LTD
|
2024-01-08 | ||
| $1.00 |
Handan Tongyi New Material Technology Co., Ltd
|
2021-12-10 | ||
|
Qiuxian Baitai New Material Co., LTD
|
2021-11-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY